CMS Electrical Continence Aid Coverage Policy (NCD 234): What Billing Teams Need to Know for 2026

The Centers for Medicare & Medicaid Services (CMS) has issued a modified version of National Coverage Determination (NCD) 234, governing electrical continence aids under the Medicare Prosthetic Devices benefit category. This policy update, effective March 12, 2026, maintains the existing non-coverage determination for electrical continence aids, citing the device's experimental status and lack of validated clinical evidence. Billing teams submitting claims to Medicare for these devices should be aware of the denial rationale and documentation requirements before submitting.

What Is an Electrical Continence Aid Under CMS NCD 234?

An electrical continence aid is a specific device category under Medicare's Prosthetic Devices benefit. Per the NCD definition, the device consists of a plastic plug molded to fit the shape of a patient's anal canal. Two electrodes are implanted within the plug and connected via wire to a small portable generator worn by the patient.

The device works by delivering an electrical current that stimulates the anal musculature, producing a contraction strong enough to retain the plug in place while the patient ambulates—the intended clinical effect being prevention of fecal incontinence during movement.

From a billing classification standpoint, this device falls under the Prosthetic Devices benefit category. However, classification within a benefit category does not guarantee coverage—CMS evaluates each item separately for medical necessity under §1862(a)(1) of the Social Security Act.

CMS Coverage Determination: Not Covered Under Medicare

CMS has determined that electrical continence aids are not covered under Medicare. The agency's rationale rests on two linked findings:

1. Experimental status — CMS considers these devices to still be in the experimental stage of development.
2. Lack of valid scientific documentation — There is no scientifically validated evidence of effectiveness or safety sufficient to meet Medicare's coverage standard.

Because of these two findings, CMS concludes that electrical continence aids cannot be considered "reasonable and necessary" for the treatment of an illness or injury, or for improving the functioning of a malformed body member—the statutory standard required under §1862(a)(1) of the Act.

This is a hard non-coverage position. There are no exceptions, no prior authorization pathways, and no coverage criteria that, if met, would allow a claim to pass. This is not a "coverage with conditions" scenario—it is a categorical exclusion.

Affected Codes

This policy does not list specific CPT or HCPCS codes. CMS has not assigned billable procedure codes to electrical continence aids under NCD 234. There are no ICD-10-CM diagnosis codes listed in the policy as relevant to coverage criteria.

No covered codes exist under this policy.

Non-coverage summary:

Because no specific HCPCS or CPT codes are cited in the policy, billing teams should not attempt to identify an alternate code to route claims through. If a miscellaneous HCPCS code is used on a claim that describes this device, expect a denial citing NCD 234 as the basis.

Why CMS Non-Coverage Determinations Based on Experimental Status Matter to Revenue Cycle Teams

When CMS designates a device or service as experimental under an NCD, the implications for your revenue cycle are specific and predictable. Claims submitted for a non-covered item under an NCD will deny on the basis of medical necessity—and that denial is not typically overturnable on appeal without a change to the underlying NCD.

This differs from a Local Coverage Determination (LCD) denial, which may allow more flexibility in the appeals process with supporting clinical documentation. An NCD is a national-level binding policy, meaning no Medicare Administrative Contractor (MAC) can override it locally, and no amount of physician attestation or clinical notes will convert a denied claim into a paid one.

For practices or DME suppliers that have encountered patient requests for this device, the appropriate action is a financial counseling conversation before the device is provided—not after a claim denial.

Advance Beneficiary Notice (ABN) Considerations

Although this device is non-covered under Medicare, patients may still choose to obtain one and pay out of pocket. In that scenario, an Advance Beneficiary Notice of Noncoverage (ABN) should be issued before the device is provided. The ABN informs the Medicare beneficiary that Medicare will not pay for the item and allows them to make an informed decision about whether to proceed at their own expense.

Issuing an ABN correctly protects your practice or supplier from liability for the claim amount. Failing to issue an ABN when required—and then billing the patient—can create compliance exposure. Review your ABN workflow for any device categories flagged as non-covered under an NCD to ensure this step is consistently executed.

What Your Billing Team Should Do